News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
69,991 Results
Type
Article (1928)
Company Profile (2)
Press Release (68061)
Section
Business (21464)
Career Advice (9)
Deals (4553)
Drug Development (8164)
FDA (1804)
Job Trends (800)
News (37026)
Policy (3561)
Tag
Academia (93)
Allergies (5)
Alliances (8134)
ALS (6)
Alzheimer's disease (123)
Antibody-drug conjugate (ADC) (13)
Approvals (1835)
Artificial intelligence (14)
Automation (1)
Bankruptcy (8)
Best Places to Work (585)
Biosimilars (22)
Biotechnology (5)
Bladder cancer (11)
Brain cancer (2)
Breast cancer (21)
Cancer (222)
Cardiovascular disease (5)
Career advice (9)
CAR-T (4)
Cell therapy (25)
Clinical research (7038)
Collaboration (94)
Compensation (9)
Complete response letters (2)
COVID-19 (185)
C-suite (16)
Cystic fibrosis (4)
Data (202)
Depression (1)
Diabetes (14)
Diagnostics (599)
Digital health (1)
Drug discovery (13)
Duchenne muscular dystrophy (12)
Earnings (7639)
Events (7005)
Executive appointments (50)
FDA (1955)
Fibrodysplasia Ossificans Progressiva (1)
Funding (60)
Gene editing (3)
Gene therapy (19)
GLP-1 (45)
Government (233)
Grass and pollen (1)
Guidances (4)
Healthcare (1076)
IgA nephropathy (4)
Immunology and inflammation (1)
Indications (3)
Infectious disease (192)
Inflammatory bowel disease (17)
Influenza (6)
Intellectual property (17)
IPO (1626)
Job creations (241)
Job search strategy (9)
Layoffs (6)
Legal (951)
Liver cancer (16)
Lung cancer (36)
Lymphoma (15)
Manufacturing (31)
MASH (7)
Medical device (1122)
Medtech (1123)
Mergers & acquisitions (3024)
Metabolic disorders (39)
Multiple sclerosis (8)
NASH (1)
Neurodegenerative disease (7)
Neuroscience (168)
NextGen: Class of 2025 (220)
Non-profit (62)
Obesity (16)
Opinion (1)
Ovarian cancer (10)
Pain (4)
Pancreatic cancer (8)
Parkinson's disease (15)
Partnered (2)
Patents (19)
Patient recruitment (8)
People (4970)
Pharmaceutical (3)
Phase I (1909)
Phase II (2951)
Phase III (2664)
Pipeline (125)
Postmarket research (241)
Preclinical (668)
Press Release (2)
Prostate cancer (8)
Radiopharmaceuticals (22)
Rare diseases (27)
Real estate (600)
Regulatory (2604)
Reports (6)
Research institute (92)
Schizophrenia (7)
Series A (15)
Series B (7)
Service/supplier (1)
Sickle cell disease (1)
Spinal muscular atrophy (4)
Startups (422)
Stomach cancer (1)
Supply chain (8)
Vaccines (24)
Venture capitalists (2)
Weight loss (2)
Women's health (1)
Date
Today (11)
Last 7 days (71)
Last 30 days (218)
Last 365 days (2928)
2025 (895)
2024 (3253)
2023 (3820)
2022 (7012)
2021 (6373)
2020 (5874)
2019 (3864)
2018 (3014)
2017 (3560)
2016 (3171)
2015 (4030)
2014 (3020)
2013 (2600)
2012 (2775)
2011 (2902)
2010 (2663)
Location
Africa (79)
Alabama (1)
Arizona (8)
Asia (21394)
Australia (2433)
California (352)
Canada (225)
China (165)
Colorado (4)
Connecticut (14)
Delaware (4)
Europe (12463)
Florida (22)
Georgia (7)
Illinois (16)
India (11)
Indiana (4)
Japan (82)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (75)
Massachusetts (244)
Michigan (2)
Minnesota (27)
Missouri (3)
Nebraska (1)
Nevada (1)
New Jersey (202)
New York (148)
North Carolina (61)
Northern California (138)
Ohio (2)
Oregon (1)
Pennsylvania (55)
South America (106)
Southern California (162)
Tennessee (1)
Texas (28)
United States (1329)
Utah (13)
Virginia (25)
Washington D.C. (2)
Washington State (17)
Wisconsin (6)
69,991 Results for "chemomab ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chemomab Announces New Medical and Clinical Appointments
April 16, 2025
·
9 min read
Press Releases
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
April 21, 2025
·
3 min read
Press Releases
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
March 7, 2025
·
11 min read
Press Releases
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
April 29, 2025
·
8 min read
Press Releases
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
March 3, 2025
·
16 min read
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - May 17, 2024
Chemomab Therapeutics Ltd. today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
May 17, 2024
·
3 min read
Press Releases
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025
·
2 min read
Press Releases
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
March 28, 2025
·
13 min read
Business
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
April 24, 2024
·
1 min read
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC).
June 18, 2024
·
6 min read
1 of 7,000
Next
